Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Tocris Bioscience™ BAY 598

Catalog No. p-7161602
Change view
Click to view available options
Quantity:
5 mg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
59-915 5 mg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
This item is not returnable. View return policy
Catalog No. 59-915 Supplier Tocris Bioscience™ Supplier No. 5991/5
This item is not returnable. View return policy

Potent and selective SMYD2 inhibitor

BAY 598 is a potent and selective competitive inhibitor of SMYD2 lysine methyltransferase (IC50 values are 27 and 58 nM for biochemical and cellular activity assays, respectively), which displays >100-fold selectivity for SMYD2 over a panel of 32 other methyltransferases including SMYD3, SUV420H1, and SUV420H2. BAY 598 enhances apoptotic responses to doxorubicin (Cat. No. 2252) in cancer cell lines, and decreases p53K370me levels in HEK293 cells. It also reduces methylation in tumor cells in a mouse xenograft model.

To request the negative control for BAY 598, please fill out the BAY 369 request form on the SGC website.

Specifications

Chemical Name or Material N-[(4 S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1 H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide
CAS 1906919-67-2
Quantity 5 mg
Target Additional Lysine Methyltransferase Compounds
Molecular Formula C22H20Cl2F2N6O3
Formula Weight 525.34
Purity 98%
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.